• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性低氧和野百合碱诱导肺动脉高压过程中肺 microRNA 谱的动态变化。

Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.

机构信息

Division of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, 126 University Ave, University of Glasgow, Glasgow, Scotland.

出版信息

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):716-23. doi: 10.1161/ATVBAHA.109.202028. Epub 2010 Jan 28.

DOI:10.1161/ATVBAHA.109.202028
PMID:20110569
Abstract

OBJECTIVE

MicroRNAs (miRNAs) are small noncoding RNAs that have the capacity to control protein production through binding "seed" sequences within a target mRNA. Each miRNA is capable of potentially controlling hundreds of genes. The regulation of miRNAs in the lung during the development of pulmonary arterial hypertension (PAH) is unknown.

METHODS AND RESULTS

We screened lung miRNA profiles in a longitudinal and crossover design during the development of PAH caused by chronic hypoxia or monocrotaline in rats. We identified reduced expression of Dicer, involved in miRNA processing, during the onset of PAH after hypoxia. MiR-22, miR-30, and let-7f were downregulated, whereas miR-322 and miR-451 were upregulated significantly during the development of PAH in both models. Differences were observed between monocrotaline and chronic hypoxia. For example, miR-21 and let-7a were significantly reduced only in monocrotaline-treated rats. MiRNAs that were significantly regulated were validated by quantitative polymerase chain reaction. By using in vitro studies, we demonstrated that hypoxia and growth factors implicated in PAH induced similar changes in miRNA expression. Furthermore, we confirmed miR-21 downregulation in human lung tissue and serum from patients with idiopathic PAH.

CONCLUSIONS

Defined miRNAs are regulated during the development of PAH in rats. Therefore, miRNAs may contribute to the pathogenesis of PAH and represent a novel opportunity for therapeutic intervention.

摘要

目的

微小 RNA(miRNAs)是一类小的非编码 RNA,通过与靶 mRNA 中的“种子”序列结合,具有控制蛋白质产生的能力。每个 miRNA 都有可能控制数百个基因。肺内 miRNA 在肺动脉高压(PAH)发展过程中的调控尚不清楚。

方法和结果

我们采用慢性低氧或野百合碱诱导大鼠 PAH 的纵向和交叉设计筛选肺 miRNA 谱。我们发现,低氧诱导 PAH 发病时 miRNA 加工相关的 Dicer 表达降低。miR-22、miR-30 和 let-7f 在两种模型的 PAH 发展过程中均显著下调,而 miR-322 和 miR-451 则显著上调。野百合碱和慢性低氧之间存在差异。例如,仅在野百合碱处理的大鼠中,miR-21 和 let-7a 显著降低。通过定量聚合酶链反应验证了显著调节的 miRNAs。通过体外研究,我们证明了低氧和与 PAH 相关的生长因子诱导了 miRNA 表达的相似变化。此外,我们还证实了 miR-21 在特发性 PAH 患者的肺组织和血清中的下调。

结论

在大鼠 PAH 发展过程中,特定的 miRNAs 受到调节。因此,miRNAs 可能有助于 PAH 的发病机制,并为治疗干预提供了新的机会。

相似文献

1
Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.慢性低氧和野百合碱诱导肺动脉高压过程中肺 microRNA 谱的动态变化。
Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):716-23. doi: 10.1161/ATVBAHA.109.202028. Epub 2010 Jan 28.
2
Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension.在肺动脉高压动物模型中微小RNA失调的逆转
PLoS One. 2016 Jan 27;11(1):e0147827. doi: 10.1371/journal.pone.0147827. eCollection 2016.
3
Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.Let-7a转染的间充质干细胞通过STAT3-BMPR2信号通路抑制肺动脉平滑肌细胞生长,从而改善野百合碱诱导的肺动脉高压。
Stem Cell Res Ther. 2017 Feb 10;8(1):34. doi: 10.1186/s13287-017-0480-y.
4
miR-223 reverses experimental pulmonary arterial hypertension.微小RNA-223可逆转实验性肺动脉高压。
Am J Physiol Cell Physiol. 2015 Sep 15;309(6):C363-72. doi: 10.1152/ajpcell.00149.2015. Epub 2015 Jun 17.
5
Discordant Regulation of microRNA Between Multiple Experimental Models and Human Pulmonary Hypertension.多种实验模型与人类肺动脉高压之间微小RNA的不一致调控
Chest. 2015 Aug;148(2):481-490. doi: 10.1378/chest.14-2169.
6
Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension.鉴定终末期特发性肺动脉高压中靶向Wnt/β-连环蛋白通路的微小RNA
J Mol Med (Berl). 2016 Aug;94(8):875-85. doi: 10.1007/s00109-016-1426-z. Epub 2016 May 18.
7
LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.长链非编码 RNA-SMILR 通过靶向 miR-141 调节 RhoA/ROCK 信号通路,从而调节肺动脉高压中的血管重构。
Am J Physiol Heart Circ Physiol. 2020 Aug 1;319(2):H377-H391. doi: 10.1152/ajpheart.00717.2019. Epub 2020 Jun 19.
8
Dysregulation of miR-135a-5p promotes the development of rat pulmonary arterial hypertension in vivo and in vitro.miR-135a-5p 的失调促进了大鼠肺动脉高压在体和体外的发展。
Acta Pharmacol Sin. 2019 Apr;40(4):477-485. doi: 10.1038/s41401-018-0076-9. Epub 2018 Jul 23.
9
Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease.肺动脉高压大鼠模型中骨形态发生蛋白和转化生长因子-β信号的改变:激活素受体样激酶-5抑制在疾病预防和进展中的潜力
Circulation. 2009 Feb 3;119(4):566-76. doi: 10.1161/CIRCULATIONAHA.108.821504. Epub 2009 Jan 19.
10
Endothelial-to-mesenchymal transition in pulmonary hypertension.肺高血压中的内皮细胞-间充质转化。
Circulation. 2015 Mar 17;131(11):1006-18. doi: 10.1161/CIRCULATIONAHA.114.008750. Epub 2015 Jan 15.

引用本文的文献

1
Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children.儿童肺动脉高压所致右心室衰竭的机制与治疗
Children (Basel). 2025 Apr 7;12(4):476. doi: 10.3390/children12040476.
2
Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.肺动脉高压:分子机制与临床研究
MedComm (2020). 2025 Mar 10;6(3):e70134. doi: 10.1002/mco2.70134. eCollection 2025 Mar.
3
Targeting Soluble TGF-β Factors: Advances in Precision Therapy for Pulmonary Arterial Hypertension.靶向可溶性转化生长因子-β因子:肺动脉高压精准治疗的进展
JACC Basic Transl Sci. 2024 Jun 19;9(11):1360-1374. doi: 10.1016/j.jacbts.2024.04.005. eCollection 2024 Nov.
4
Unraveling the role of HIF and epigenetic regulation in pulmonary arterial hypertension: implications for clinical research and its therapeutic approach.解析缺氧诱导因子(HIF)和表观遗传调控在肺动脉高压中的作用:对临床研究及其治疗方法的启示
Front Med (Lausanne). 2024 Oct 10;11:1460376. doi: 10.3389/fmed.2024.1460376. eCollection 2024.
5
Cardiovascular Disease and miRNAs: Possible Oxidative Stress-Regulating Roles of miRNAs.心血管疾病与微小RNA:微小RNA可能的氧化应激调节作用
Antioxidants (Basel). 2024 May 27;13(6):656. doi: 10.3390/antiox13060656.
6
Whole-genome microRNA sequencing analysis in patients with pulmonary hypertension.肺动脉高压患者的全基因组微小RNA测序分析
Front Genet. 2023 Nov 16;14:1250629. doi: 10.3389/fgene.2023.1250629. eCollection 2023.
7
Stem cell therapy in pulmonary hypertension: current practice and future opportunities.肺动脉高压的干细胞治疗:现状与未来机遇。
Eur Respir Rev. 2023 Sep 27;32(169). doi: 10.1183/16000617.0112-2023. Print 2023 Sep 30.
8
Loss of microRNA-30a and sex-specific effects on the neonatal hyperoxic lung injury.miR-30a 的缺失及其对新生鼠高氧肺损伤的性别特异性影响。
Biol Sex Differ. 2023 Aug 8;14(1):50. doi: 10.1186/s13293-023-00535-6.
9
Pathophysiology and new advances in pulmonary hypertension.肺动脉高压的病理生理学与新进展
BMJ Med. 2023 Mar 23;2(1):e000137. doi: 10.1136/bmjmed-2022-000137. eCollection 2023.
10
Decreased circulating microRNA-21 and microRNA-143 are associated to pulmonary hypertension.循环 microRNA-21 和 microRNA-143 的减少与肺动脉高压有关。
Turk J Med Sci. 2023 Feb;53(1):130-141. doi: 10.55730/1300-0144.5566. Epub 2023 Feb 22.